Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.42 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406987 | 0.87 | KEAP1 (0.46) | PTGER1C5AR1OXTRLMNATSHR | |
| SCHEMBL8990081 | 0.79 | C5AR1 (0.53) | C5AR1LMNA | |
| SCHEMBL2176667 | 0.77 | MEN1 (0.48) | PTGER1C5AR1OXTRLMNAMEN1 | |
| SCHEMBL12407491 | 0.75 | MEN1 (0.46) | PTGER1C5AR1LMNAMEN1KMT2A | |
| SCHEMBL4449965 | 0.74 | PTGER1 (0.53) | PTGER1OXTRLMNAMEN1KMT2A | |
| SCHEMBL12406996 | 0.72 | MEN1 (0.57) | PTGER1OXTRLMNAMEN1KMT2A | |
| SCHEMBL2176662 | 0.72 | PTGER1 (0.52) | PTGER1OXTRLMNAMEN1KMT2A | |
| SCHEMBL2176077 | 0.71 | KEAP1 (0.64) | PTGER1OXTRLMNAMEN1KMT2A | |
| SCHEMBL8762519 | 0.71 | CA9 (0.53) | LMNAMEN1KMT2ACYP2C9 | |
| SCHEMBL12407191 | 0.70 | HPGD (0.57) | PTGER1OXTRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | PTGER1 1/4885C5AR1 1657/4885OXTR 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.